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1ABSTRACT
Functional validation of Cell Division Cycle Associated 8 (CDCA8) 
as a novel therapeutic target in Human Hepatocellular Carcinoma
Tae-Won Jeon
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Young Nyun Park)
Hepatocellular carcinoma (HCC) is the third most lethal cancer worldwide and 
remains a major challenge due to poor prognosis and limited treatment options. 
Cell Division Cycle Associated 8 (CDCA8) is known as a component of a 
chromosomal passenger complex required for stability of the bipolar mitotic 
spindle and it is commonly overexpressed in human HCC. However, the role of 
CDCA8 in HCC remains indefinable. In this study, we tested the hypothesis 
that specific targeting of CDCA8 is sufficient to inhibit HCC progression. Small 
interfering RNA (siRNA)-mediated silencing of CDCA8 inhibited HCC cell 
2growth by blocking cell-cycle progression, inducing apoptosis. Next generation 
sequencing (NGS) expression analysis of CDCA8 knockdown signature showed 
that CDCA8 blockade caused anti-proliferative effects. These effects were also 
associated with dysregulation of CDCA8-regulated genes that control cell cycle 
and apoptosis. Anti-proliferative effects were driven by a subset of molecular 
alterations including the upregulation of ATF3 and GADD34, whereas a key 
regulator of cell growth and invasiveness BGLAP was repressed. Subsequent 
Western blotting revealed that CDCA8 silencing also decreased the level of 
pro-caspase 3 and PARP-1, accelerating apoptotic signaling in HCC cells.
Taken together, these findings offer a preclinical proof-of-concept that CDCA8 
can be a promising molecular target for systemic therapy of HCC.
------------------------------------------------------------------------------------------------
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I. INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common neoplasms
worldwide and the third leading cause of cancer-related mortality with annual 
death exceeding 600,000.1,2 Similarly, about 14,000 annual incidence of HCC 
has been reported in South Korea. Even with advanced treatment, HCC usually 
has a poor prognosis, with a 5-year survival rate of patients as low as 25%-39% 
after curative treatments such as surgical resection, liver transplantation, 
chemotherapy, and radiotherapy.3,4 Generally, only 30%-40% of HCC patients 
4are diagnosed as eligible for current curative treatment due to late diagnosis, 
high recurrence rate, underlying liver disease and a lack of effective treatment 
options.5 It is widely accepted that environmental factors and additional genetic 
and epigenetic alterations associated with development of HCC.6 Although the 
risk factors for HCC are well characterized and there are ongoing efforts, the 
molecular mechanism of HCC carcinogenesis is not well understood. Therefore 
the identification of efficient new targets for the inhibition of HCC must be 
urgently needed. 
Cell cycle deregulation is one of the hallmarks in various cancer types and, thus, 
recognition of targets underlying regulatory mechanisms for cell cycle 
regulation is critical in the development of effective cancer therapies.7,8 In a 
previous study, cell division cycle associated 8 (CDCA8) is associated with in 
cell cycle progression.9 CDCA8, also called as Borealin or Darsa B, is known as 
a component of a chromosomal passenger complex, which acts as a key 
regulator of mitosis, required for stability of cell division and it is commonly 
overexpressed in a series of solid tumors, including HCC.10,11 However, the 
underlying molecular mechanisms of CDCA8 on HCC cells have not yet been 
clearly demonstrated. 
In the present study, our aim was to investigate the role of CDCA8 on Huh-1 
5and Huh-7 HCC cells and to elucidate the molecular mechanism. CDCA8 
knockdown via RNAi markedly suppressed these phenotypes in Huh-1 and 
Huh-7 HCC cell lines. CDCA8 knockdown inhibited HCC cell growth and 
long-term colony formation. It also induced apoptosis and cell cycle arrest. We 
also performed RNA sequencing and subsequent protein analysis to understand 
the molecular mechanism on a whole genome scale. The growth inhibitory 
effects were induced through a subset of molecular alterations, including the 
upregulation of ATF3 and GADD34, which play a pivotal role in apoptotic 
progression. These results may provide further insight into HCC progression 
and suggest that CDCA8 may be a potential therapeutic target in HCC.
6II. MATERIALS AND METHODS
1. Cell culture and siRNA transfection
Liver cancer cell lines, Huh-1 and Huh-7 were purchased from the Japanese 
Cellection of Research Biosources Cell Bank (JCRB). Huh-1 and Huh-7 cells 
were cultured in DMEM medium (HyClone, South Logan, UT, USA) 
supplemented with 10% fetal bovine serum (HyClone) and 1% 
penicillin/streptomycin solution (HyClone) at 37℃ with 5% CO2. The 
phenotypes of these cell lines have been authenticated by the JCRB. Cells were 
plated at 30% density 24hr before transfection. Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA) was mixed with siRNA molecules in Opti-MEM 
(Invitrogen, Carlsbad, CA, USA). The medium was replaced 24hr after 
transfection. CDCA8 siRNA duplexes were chemically synthesized by Ambion 
(Austin, TX, USA) (CDCA8: siRNA ID# s30269). The negative control siRNA 
(NC siRNA) molecules that do not target any endogenous transcript were used 
for control experiments. The sequences of NC siRNA (Bioneer, Daejeon, South 
Korea) were as following : 5’-ACGUGACACGUUCGGAGAA(UU)-3’(sense) 
and 5’-UUCUCCGAACGUGUCACGU-3’(antisense).
72. Measurement of cell proliferation and apoptotic cell death
The cell growth was measured using the CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay (Promega, Medison, WI, USA) according to the 
manufacturer’s instructions. For the measurement of cell proliferation and 
apoptosis, cells were seeded at 30% confluence in 96-well plates in culture 
media without antibiotics one day before transfection. The cells were 
transfected as described above and incubated for 2hr at 37℃ in a humidified, 5% 
CO2 atmosphere. The colored formazan products were determined by measuring 
the absorbance at 490 nm using a VersaMax microplate reader (Molecular 
Device, Sunnyvale, CA, USA). The level of caspase-cleaved keratin 18 (ccK18) 
fragments was detected using M30 Apoptosense ELISA (PETIVA, Bromma, 
Sweden) as recommended by the manufacturer.  
3. Clonogenic assay
Cells transfected with siRNA were seed in 6-well culture plates at 1x103 cells 
per well. Cells were maintained in culture for 12 days without medium change 
to let the viable cells propagate to sizable colonies for quantification. The 
colonies were fixed with methanol and then stained with 0.5% crystal violet for 
30min at room temperature. The number of colonies formed in each well was 
8counted under the microscope. 
4. Real-time RT-PCR
The changes in target gene expression on mRNA level were detected using 
real-time quantitative RT-PCR. Total RNA was isolated using TRIzol (Ambion 
Inc., Texas, USA) and synthesized to cDNA by using 1st strand cDNA Synthesis 
Kit (Takara Biotech, Kusatsu, Shiga, Japan) according to the manufacturer’s 
instruction. cDNA of CDCA8 gene GAPDH were amplified using
corresponding  pair of primers (CDCA8 forward, 5’-GCAGGAGAGCGGATT
TACAAC-3’; CDCA8 reverse, 5’-CTGGGCAATACTGTGCCTCTG-3’ and 
GAPDH forward, 5’ GGGAGCCAAAAGGGTCATCATCTC-3’; GAPDH 
reverse, 5’-CCATGCCAGTGAGCTTCCCGTTC-3’) synthesized by Macrogen 
Inc. (Seoul, South Korea). The relative quantification of mRNA was measured 
by LightCycler 96 (Roche, Basel, Switzerland) according to the manufacturer’s 
instructions and quantified using LightCycler 96 software version 1.1, 
comparing with the Ct (threshold cycle) values of each target gene. The mRNA 
levels of GAPDH were used for normalization. 
95. Cell cycle analysis 
Cells were cultured in 60mm culture dishes and harvested 48hr later after 
siRNA transfection. Cells were washed with cold PBS, and then fixed 24hr with 
70% cold ethanol at -20℃. Cells were washed with cold PBS again and 
incubated in the dark with in Propidium Iodide (PI) staining solution with 
RNase A (BD Biosciences, SanDiego, CA) for 30min at room temperature. The
cell cycle was measured by FACSVerse flow cytometry (BD Bioscience, 
SanDiego, CA) according to the manufacturer’s instructions and quantified 
using FlowJo software program.
6. Detection of apoptosis
Annexin V and PI dual staining was used to detect apoptosis cells in a similar 
procedure as described above but the cells were not fixed with 70% ethanol. 
Apoptotic cells were stained using FITC Annexin V Apoptosis Detection Kit I
(BD Bioscience, SanDiego, CA) following the manufacturer’s instruction. The 
cell death was measured by FACSVerse flow cytometry (BD Bioscience, 
SanDiego, CA) and quantified using FlowJo software program.
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7. RNA sequencing
Total RNA was extracted 48hr after siRNA transfection using the RNeasy mini 
kit (Qiagen, Valencia, CA, USA). The quantity of the total RNA was evaluated 
using RNA electropherograms (Bio-Rad Experion, Hercules, CA, USA); RNA 
quality was assessed based on the RNA quality indicator (RQI). The total RNA 
from each sample with a RQI value of 8.0 or higher was used. The resulting 
mRNA samples were processed for sequencing libraries using the Illumina 
TruSeq Stranded mRNA sample preparation kit (Illumina, San Diego, CA, USA) 
according to the manufacturer’s protocols. RNA sequencing was performed 
using the Illumina HiSeq 2500 to generate non-directional, paired-end 
100-base-pair reads. Quality-filtered reads were mapped to the human reference 
genome sequence hg19 (UCSC Genome Bioinformatics, 
https://genome.ucsc.edu) using tophat2 (http://ccb.jhu.edu/software/tophat). The 
relative transcript abundance was estimated by counting the fragments per 
kilobase of the exon model per million mapped sequence reads (FPKM), and 
differentially expressed genes were evaluated using the cufflinks package 
(http://cole-trapnell-lab.github.io/cufflinks). The significantly overlapping 
pathways and Gene Ontology categories with differentially expressed genes 
were analyzed using DAVID (http://david.abcc.ncifcrf.gov).
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8. Western blot analysis
Cells were suspended in RIPA buffer (Thermo Scientific, Rockford, IL, USA) 
containing 0.01% of a protease and phosphatase inhibitor cocktail (Thermo 
Scientific) 48hr after siRNA transfection. The amount of protein was quantified 
by using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, 
USA). Equal amounts (50 ug) of total proteins were fractionated by SDS-PAGE 
on a 10% gel and transferred to PVDF membranes (Roche, Basel, Switzerland). 
The membrane was blocked with 5% milk/Tris-buffered saline plus Tween 20 
(TBST) and incubated with primary antibodies against human ATF-3 (sc-188), 
GADD34 (sc-8327), p-cdc2 (sc-12341), pro-caspase 3 (sc-7272), PARP-1 
(sc-8007) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), cyclin B 
(ab72) and CDCA8 (ab70910, Abcam, Cambridge, UK). HRP goat anti-mouse 
IgG and HRP goat anti-rabbit IgG (Santa Cruz) were used as the secondary 
antibodies. Immunoreactive bands were visualized with an LAS-3000 Imager 
(Fujifilm Corporation, Tokyo, Japan). Equal loading was assessed by probing 
the same membrane with a β-actin antibody (Santa Cruz).
12
9. Statistical analysis
All data were obtained at least three independent experiments and are presented 
as mean ± SE (Standard Error), unless otherwise indicated. Statistical analysis 
was performed using one-way ANOVA and Student’s t-test. Data were 
considered significant if *p<0.05, **p<0.01. 
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III. RESULTS
1. CDCA8 knockdown inhibits HCC cell proliferation and long-term 
colony formation
To examine the biological effects of CDCA8 knockdown, two HCC cell lines, 
Huh-1 and Huh-7, were transfected with CDCA8-specific siRNA. To select the 
siRNA eliciting the highest treatment efficacy and target gent knockdown, we 
tested a 10 to 20 nmol/L dose range for CDCA8 siRNA at optimal experimental 
conditions. Cells were plated at 30% confluence 24hr before transfection and 
treated with siRNA mixed with the lipofectamine. After evaluating the 
efficiency of siRNA, CDCA8 siRNA at a concentration of 15 nmol/L was 
considered appropriate for CDCA8 knockdown. Notably, CDCA8 siRNA at a 
concentration of 15 nmol/L caused a maxium growth suppression of 
approximately 70% in both the Huh-1 and Huh-7 cells after 4 days of treatment
(Figure 1A). This dose was, therefore, selected for all subsequent studies. 
Consistent with the phenotypic result, CDCA8 siRNA was also effective in 
silencing CDCA8 mRNA in both of the examined HCC cells, when compared 
with NC siRNA which was not able to knock down expression of any gene
(Figure 1B). CDCA8 knockdown was specific as transfection with NC siRNA 
did not affect target gene expression. The decrease in cell viability was affirmed
14
by microscopic observation in 4 days of target gene silencing (Figure 2). To 
further investigate the long-term effect of CDCA8 knockdown, colony 
formation experiment was performed. Consistent with the results of the 
short-term phenotypic assay, CDCA8 knockdown was also effective in 
inhibiting long-term colony formation (Figure 3A). CDCA8 siRNA caused a 
strong reduction of the growth about 70% and 80% in Huh-1 and Huh-7 cells, 
respectively (Figure 3B). Taken together, these data indicated that 
siRNA-mediated knockdown of CDCA8 in HCC cells inhibit cellular 
proliferations and colony formation of HCC cells. 
15
Figure 1. siRNA knockdown of CDCA8 suppresses HCC cell proliferation. 
(A) Kinetics of growth inhibition in Huh-1 and Huh-7 cells treated with 
15nmol/L NC siRNA and CDCA8 siRNA. The data represent three independent 
experiments. (B) Down-regulation of CDCA8 mRNA in Huh-1 and Huh-7 cells 
48hr after transfection with 15nmol/L CDCA8 siRNA. The data expressed 
relative to GAPDH and normalized to NC siRNA treatment. All statistical 
analysis was performed using Bootstrap t-test. *P<0.05; **P<0.01. 
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Figure 2. siRNA knockdown of CDCA8 inhibits growth of HCC cells. 
Representative light microscopy images of Huh-1 and Huh-7 cells 4 days after 
transfection with NC siRNA and CDCA8 siRNA. Scale bar, 100m. NC siRNA, 
negative control siRNA. 
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Figure 3. siRNA knockdown of CDCA8 inhibits long-term colony 
formation in HCC cells. (A) Observation of colony formation in Huh-1 and 
Huh-7 cells, using a clonogenic assay 12 days after transfection with 15nmol/L 
NC siRNA and CDCA8 siRNA. (B) Measurement of number of colonies 
formed in Huh-1 and Huh-7 cells. The data represent three independent 
experiments. **P<0.01 using the Poisson generalized linear model. 
18
2. CDCA8 knockdown influences cell cycle progression and induces 
apoptosis in HCC cells
To evaluate the effect of CDCA8 knockdown on the cell cycle, flow cytometry 
was performed to detect the cell cycle distribution of Huh-1 and Huh-7 cells
(Figure 4). Fluorescence-activated cell sorting (FACS) analysis revealed 
accumulation of G2/M-phase cells and a concomitant decrease in the 
G0/G1-phase cells in both examined HCC cell lines 2 days after treatment with 
CDCA8-siRNA when compared with the NC siRNA, which was used as control 
(Figure 5). These results supported the theory that CDCA8 knockdown may 
contribute to the cell division via promoting the progression of the G2/M phase 
in the cell cycle.12 More significantly, the growth inhibition and cell cycle arrest 
might reflect the strong induction of apoptosis as measured through the 
detection of the apoptotic marker Annexin V using FACS (Figure 6). In other 
words, at 48hr after transfection with CDCA8 siRNA, the percentage of 
early-apoptotic cell populations (Q3 region) plus late-apoptotic cell populations 
(Q2 region) in Huh-1 and Huh-7 cells increased by about 29% and 90%, 
respectively. To confirm the apoptotic induction through CDCA8 knockdown, 
we conducted an ELISA assay to detect the cleaved K18 in apoptotic cells but 
not in the necrotic cells. Namely, HCC cells with silenced CDCA8 showed a 
19
strong induction of apoptosis as measured by an accumulation of 
apoptosis-specific caspase-cleaved K18 (ccK18) fragments (Figure 7B). The 
results showed that CDCA8 knockdown significantly increased the cleaved K18 
fragments in Huh-1 and Huh-7 cells approximately 1.5- and 1.3- fold, 
respectively, at 48hr after transfection with CDCA8 siRNA. Therefore, these 
data demonstrated that siRNA-mediated knockdown of CDCA8 in HCC cells 
induces cell cycle arrest and increases propensity to undergo apoptotic cell 
death. 
20
Figure 4. CDCA8 silencing delays cell-cycle progression in HCC cells. 
FACS analysis of cell-cycle progression at 48hr after transfection with NC 
siRNA and CDCA8 siRNA. The distribution of cell cycle was analyzed using PI 
staining and the proportion of DNA in the different phase was calculated using 
FlowJo software. Representative histograms of cell cycle distribution from three 
independent experiments are shown.
21
Figure 5. CDCA8 silencing induces cell-cycle arrest in HCC cells. (A) Cell 
cycle distribution (G0/G1, S, and G2/M) of Huh-1 and Huh-7 cells. HCC cells 
were treated with siRNA and cells were processed for flow cytometric analysis. 
Flow cytometry analysis of HCC cells treated with siRNA confirmed cell cycle 
arrest in G2/M. The data represent three independent experiments. *P<0.05 by 
Student’s t-test with equal variance.
22
Figure 6. CDCA8 silencing induces apoptosis in HCC cells. Detection of the 
apoptotic cell population through FACS analysis with the intensity of apoptotic 
marker Annexin V at 48hr after transfection with 15nmol/L NC siRNA and 
CDCA8 siRNA. Representative results from three independent experiments are 
shown.
23
Figure 7. siRNA knockdown of CDCA8 induces apoptotic cell death in 
HCC cells. (A) Detection of the apoptotic cell population through FACS 
analysis based on the intensity of the apoptotic marker Annexin V in Huh-1 and 
Huh-7 cells at 48hr after transfection with 15nmol/L NC siRNA and CDCA8 
siRNA. (B) Detection of caspase-cleaved keratin 18 (ccK18) fragments by M30 
Apoptosense ELISA 2 days after transfection experiments. The data represent 
three independent experiments. All statistical analysis was performed using 
Bootstrap t-test. *P<0.05; **P<0.01. 
24
3. The molecular mechanisms underlying the growth inhibitory 
effects of CDCA8 knockdown in HCC cell
To study the molecular basis of the observed growth inhibition caused by 
CDCA8 silencing, we compared the global gene expression profiles of 
CDCA8-deficient Huh-1 and Huh-7 cells to those of sham-treated control cells 
using next-generation RNA sequencing. The global gene expression analysis 
revealed that CDCA8-specific knockdown resulted in the up- and 
down-regulation of 145 RNA transcripts in Huh-1 and 494 transcripts in Huh-7 
cells (Figure 8A). Comparing these two gene sets to make a distinction between 
common anti-cancer mechanisms revealed a significant overlap of 50 genes (25 
up- and 25 down-regulated genes) defined using a Bootstrap ANOVA with 
10,000 repetitions and at least a 2-fold change (P<0.001) (Figure 8B). In 
addition, this effect was considered to be a common CDCA8 knockdown 
signature in HCC cells. Ingenuity pathway analysis (IPA) showed that the 50
genes were functionally enriched in the top two networks strongly connected 
with proliferating cell nuclear antigen (PNCA, network 1) and ATF3 (network 
2), respectively (Figure 8C and 8D). Coincide with IPA analysis, CDCA8 
knockdown impacted molecular alterations in restricted number of defined 
oncogenic pathways that played a crucial role in inhibiting cell growth and 
25
induce apoptosis. Specifically, the expression levels of ATF3, which 
functionally acts as a tumor suppressor,13 and PPP1R15A, also known as growth 
arrest and DNA damage-inducible protein GADD34, which is involved in 
growth arrest,14 were induced. Subsequent Western blot analysis proved the 
common increase of the ATF3 and GADD34 tumor suppressor proteins in 
addition to a concomitant decrease of pro-caspase 3, activating apoptotic 
signaling15 and PARP-1, a nuclear enzyme essential for genomic stability16 in 
HCC cells (Figure 9). Therefore, this finding suggests that the up-regulation of 
the tumor suppressive ATF3 and GADD34 genes is an essential and common 
mechanism of growth inhibition in CDCA8 deficient HCC cells.
26
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Figure 8. Transcriptomic analysis of gene expression by RNA sequencing 
following CDCA8 siRNA treatment. (A) Venn diagrams representing the 
number of mRNA transcripts up- or down-regulated in Huh-1 and Huh-7 cells 
at 48hr after transfection with CDCA8 siRNA. (B) A heat map of the 50 
commonly deregulated genes in Huh-1 and Huh-7 cells after normalization to 
the corresponding sham-treated cells (10,000 repetitions in bootstrap ANOVA 
with contrast tests and a threshold cut-off of twofold change, **P<0.001, red 
(induced) and green (repressed), log2-based scale). (C, D) Two putative top 
networks with high scores (>19) strongly associated with PCNA (C) and  
ATF3 (D) based on Fisher’s exact test (p value < 10-19), indicating a high 
probability of biological interactions. Up- and down-regulated genes are shown 
in red and green, respectively. The genes shown in grey are associated with the 
regulated genes.
28
Figure 9. Molecular mechanisms of therapeutic response to CDCA8 
targeting. Western blot analysis of CDCA8, ATF3, GADD34, procaspase-3, 
PARP-1, and cleaved PARP-1 functionally involved in apoptotic progression 
and p-cdc2 and cyclin B involved in cell cycle regulation respectively. 
Whole-cell lysates were prepared at 48hr after transfection with CDCA8 siRNA. 
-actin was included as a loading control. 
29
IV. DISCUSSIONS
HCC is the fifth most common malignancy and the third highest cause of 
cancer-related death worldwide and its emergence is increasing.17 Cell cycle 
deregulation is one of the hallmarks in diverse types of cancers.7 CDCA8 
overexpression has been found in various types of tumors, including lung, 
gastric, colorectal, and liver cancer,11,19,20 implying that CDCA8 targeting may 
be an effective therapeutic strategy against various cancer types. However, the 
significance of CDCA8 up-regulation in HCC has remained undetermined. In 
this study, we demonstrate that siRNA-mediated knockdown of CDCA8 caused 
a consistent and strong induction of apoptotic cell death and delayed cell cycle 
progression in the examined human HCC cells. These results suggest that 
overexpression of CDCA8 may contribute to both cell survival and thus 
represent a prognostic marker for malignant conversion in HCC. 
In a previous study, CDCA8 is associated with in cell cycle progression.9
However, the molecular mechanism underlying the induction of cancer cell 
death through CDCA8 knockdown remains unclear. In this study, 
siRNA-mediated knockdown of CDCA8 induced extensive apoptosis in both 
the Huh-1 and Huh-7 HCC cell lines, as evidenced by the detection of ccK18 
fragments (Figure 6 and Figure 7). The phenotypic changes induced by CDCA8 
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knockdown were associated with the coordinated and common dysregulation of 
50 genes (Figure 8B), as assessed through a global transcriptomic analysis using 
RNA sequencing, including up-regulation of ATF3 (Figure 8D), tumor 
suppressor that plays a pivotal role in inhibiting cell proliferations.21 We also 
observed that the up-regulation of ATF3 parallels the increase of GADD34 
tumor suppressor,22 a downstream effector of ATF3,23 and decreases PARP-1, 
Caspase 3, p-cdc2, and cyclin B (Figure 9), providing mechanisms for CDCA8 
silencing mediated inhibition of cell cycle progression and induction of 
apoptosis in HCC cells. Moreover, CDCA8 silencing increased the expression 
of apoptosis-related (CYR6124,25 and Caspase 726) and tumor suppressor 
(KLF227 and CDKN2B28), which was paralleled by the down-regulation of key 
molecules involved in a wide range of cellular response to growth (BGLAP29
and ADAMTSL430) and cell cycle progression (SLBP31 and cyclin E32), and 
lipid metabolism (C/ebp33 and SGPP134). However, the complexity of CDCA8 
knockdown relation to lipid metabolism requires further investigation. In future 
studies, further investigations into the primary effect of CDCA8 knockdown 
that can elicit the growth inhibition of HCC cells via lipid metabolism are 
warranted. 
In summary, in the present study using human hepatocellular carcinoma cell 
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lines, we found out that CDCA8 knockdown caused the inhibition of cell 
proliferation and clonogenicity, induced apoptosis, and led to cell cycle arrest. 
We also provided evidence for the molecular mechanisms by which CDCA8 
silencing induces apoptosis in HCC cells. The anti-tumorigenic effects of 
CDCA8 knockdown might reflect the up-regulation of the ATF3 tumor 
suppressor. In conclusion, this study is the first report that targeting of CDCA8 
might be used as an effective approach to HCC therapy. 
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V. CONCLUSION
These data suggest that CDCA8 is an important regulator of HCC cell growth 
and survival and represent a promising molecular target for systemic therapy of 
human HCC treatment.
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ABSTRACT (IN KOREAN)
간암 치료 표적을 위한 Cell Division Cycle Associated 8 
유전자의 신규 기능 규명
<지도교수 박 영 년>
연세대학교 대학원 의과학과
전 태 원
전 세계적으로, 치사율이 높은 간암은 때늦은 진단과 효과적인 치료
법의 부재 등으로 인해 예후가 좋지 않은 양상을 보이는 편이다. 한
편, Cell Division Cycle Associated 9 (CDCA8) 유전자는
chromosomal passenger complex 의 구성요소로서, 염색체 분리에
관여하는 양 극성 방추제 안정에 필요한 물질이다. CDCA8 유전자는
간암에서 과발현된다고 알려져 있지만 그 역할에 대해서는 아직 잘
알려져 있지 않다. 그래서 본 연구에서는 CDCA8 유전자를 억제하면
간암 세포의 성장이 억제될 것이라는 가설을 확인해 보고자 하였다. 
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그 결과, RNA 간섭현상을 이용하여 CDCA8을 억제시켰더니, 세포주
기를 억제하고 세포사멸을 유도하여 간암 세포의 증식이 억제된다는
것을 확인할 수 있었고, CDCA8 유전자의 발현 억제에 대한 Next 
Generation Sequencing (NGS) 발현 분석을 하였더니 CDCA8 유전자
의 억제는 세포의 항 증식 효과를 유발한다는 걸 확인할 수 있었으며, 
이러한 효과들은 CDCA8에 의해 조절받는 유전자들의 조절장애와 연
관이 있다는 알 수 있었다. 항 증식 효과는 일련의 분자적인 변화들
에 의해 유발되었으며, 그 중 ATF3 와 GADD34는 상향 조절되었으
나, 세포증식 및 세포전이를 조절하는 BGLAP의 발현은 억제됨을 확
인하였다. 또한, CDCA8 유전자의 억제는 세포사멸 신호를 증가시키
는 caspase-3 과 PARP-1의 활성을 증가시킴을 확인하였다. 이와
같은 결과들로 보아, 본 연구의 결과는 CDCA8 유전자가 간암의 표
적치료로 사용 될 수 있는 분자적 타겟이 될 수 있을 것이라 생각된
다.
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